Amy C Shurtleff

Summary

Affiliation: Walter Reed Army Medical Center
Country: USA

Publications

  1. ncbi request reprint Bioterrorism and emerging infectious disease - antimicrobials, therapeutics and immune-modulators. SARS coronavirus
    Amy C Shurtleff
    US Army Medical Research Institute of Infectious Diseases, Virology Division, Fort Detrick, Frederick, MD 21702 5011, USA
    IDrugs 7:91-5. 2004
  2. ncbi request reprint TMC-114 (Tibotec)
    Amy C Shurtleff
    Department of Molecular Virology, United States Army Medical Research Institute for Infectious Diseases, Fort Detrick, MD 21702, USA
    Curr Opin Investig Drugs 5:879-86. 2004
  3. pmc Development of a new vaccine for the prevention of Lassa fever
    Thomas W Geisbert
    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA
    PLoS Med 2:e183. 2005
  4. ncbi request reprint Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses
    Tove C Bolken
    SIGA Technologies Inc, 4575 SW Research Way, Corvallis, OR 97333, USA
    Antiviral Res 69:86-97. 2006

Collaborators

Detail Information

Publications4

  1. ncbi request reprint Bioterrorism and emerging infectious disease - antimicrobials, therapeutics and immune-modulators. SARS coronavirus
    Amy C Shurtleff
    US Army Medical Research Institute of Infectious Diseases, Virology Division, Fort Detrick, Frederick, MD 21702 5011, USA
    IDrugs 7:91-5. 2004
    ..Finally, approaches to circumventing and directing the immune response using genetic engineering will be reported...
  2. ncbi request reprint TMC-114 (Tibotec)
    Amy C Shurtleff
    Department of Molecular Virology, United States Army Medical Research Institute for Infectious Diseases, Fort Detrick, MD 21702, USA
    Curr Opin Investig Drugs 5:879-86. 2004
    ..Because of its improved antiviral and superior pharmacokinetic properties, TMC-114 was selected for clinical development. Phase II trials of TMC-114 are underway...
  3. pmc Development of a new vaccine for the prevention of Lassa fever
    Thomas W Geisbert
    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA
    PLoS Med 2:e183. 2005
    ..Currently, there are no licensed vaccines for Lassa fever, and no experimental vaccine has completely protected nonhuman primates against a lethal challenge...
  4. ncbi request reprint Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses
    Tove C Bolken
    SIGA Technologies Inc, 4575 SW Research Way, Corvallis, OR 97333, USA
    Antiviral Res 69:86-97. 2006
    ..This series of compounds represent a new class of inhibitors that may warrant further development for potential inclusion in a strategic stockpile...